CTOs on the Move

Helix Medical

www.helixmedical.com

 
Helix Medical is a Carpinteria, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Consortium for Conservation Medicine

Consortium for Conservation Medicine is a Palisades, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WELLNESSPROPOSALS

WELLNESSPROPOSALS is a Winston Salem, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arbor Hospice and Home Care

Arbor Hospice and Home Care is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Ann Arbor, MI. To find more information about Arbor Hospice and Home Care, please visit www.arborhospice.org

Hoya Vision

Driven by a passion for partnership as well as innovation, HOYA has been a partner to Eye Care Professionals for over 75 years, enabling them to give people the greatest gift, the gift of vision. We provide Eye Care Professionals with the lenses, consultation solutions and other services that help them to develop their practice while changing the way people see the world. We see them as visionaries, and everything we do is for them. Founded in Japan in 1941, today, HOYA has a presence in over 80 countries across the globe.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.